Dopamine vs. Norepinephrine for Hypotension in Very Preterm Infants With Late-onset Sepsis

Launched by MOUNT SINAI HOSPITAL, CANADA · Apr 20, 2022

Keywords

ClinConnect Summary

This clinical trial is studying the best medication to treat low blood pressure in very premature infants who may have a serious infection known as late-onset sepsis. The two medications being compared are Dopamine and Norepinephrine, which are often used to help babies whose blood pressure isn't responding to fluids. The goal is to find out which medication is safer and more effective, with hopes that using Norepinephrine might lead to lower death rates among these vulnerable infants.

To be eligible for this study, babies must be born at or before 32 weeks of pregnancy and must be more than 48 hours old. They also need to be receiving one of the two medications due to suspected infections and low blood pressure. Families participating in the trial can expect their baby to receive either Dopamine or Norepinephrine as part of their routine care, depending on what the medical team decides. This trial is important because it aims to improve treatment options for very preterm infants, helping doctors provide the best care possible based on real-world evidence.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • ≤32 weeks gestational age and \> 48 hours of life
• • Receiving primary vasopressor therapy with Dopamine or Norepinephrine in the context of suspected late-onset sepsis or necrotizing enterocolitis with systemic hypotension (defined as: culture positive or negative bloodstream infection)
• Exclusion Criteria:
• • Known chromosomal or genetic anomalies
• • Receiving primary therapy with agents other than Dopamine or Norepinephrine